Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum LMT1-48
- Development stage
- Unknown
- Lead developer
- Medytox
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum LMT1-48 is a probiotic bacterial strain, specifically a live biotherapeutic, developed for the management of obesity and reduction of body fat. Originally isolated from traditional Korean fermented foods, LMT1-48 exerts its therapeutic effects by modulating the intestinal environment and host metabolic pathways. Its mechanism of action includes the inhibition of the pro-obesity bacterium Enterobacter cloacae and the downregulation of lipogenic genes such as peroxisome proliferator-activated receptor gamma (PPARγ) in adipose tissue. Clinical studies have demonstrated that 12 weeks of oral supplementation with LMT1-48 leads to significant reductions in body fat mass, body fat percentage, and visceral fat area in overweight and obese adults, while maintaining a favorable safety profile.
- Other names
- L. plantarum LMT1-48Lactiplantibacillus plantarum LMT1-48
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on Lactobacillus plantarum LMT1-48.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus plantarum LMT1-48.